Idarucizumab

Drug Profile

Idarucizumab

Alternative Names: BI-655075; Praxbind

Latest Information Update: 20 Feb 2017

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Antidotes; Coagulants; Fab fragments; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Blood coagulation disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Blood coagulation disorders

Most Recent Events

  • 21 Dec 2016 Boehringer Ingelheim completes a phase III trial in Coagulation disorders in the US, Canada, the EU, Argentina, Australia, Brazil, Colombia, Hong Kong, India, Israel, Japan, Mexico, New Zealand, Russia, Singapore, South Africa, South Korea and Taiwan (NCT02104947)
  • 03 Dec 2016 Efficacy, pharmacokinetics and adverse event data from a phase I trial in Coagulation disorders (In volunteers) presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-2016)
  • 15 Nov 2016 Updated adverse event and efficacy data from phase III RE-VERSE AD trial in Coagulation disorders released by Boehringer Ingelheim
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top